Abstract
PTH is an exciting new treatment option for postmenopausal women and hypogonadal men who have osteoporosis. As an anabolic agent that affects bone metabolism, it represents an entirely new class of medication for osteoporosis and a novel approach to reducing fracture risk. Numerous clinical trials have demonstrated increases in trabecular and cortical BMD (trabecular more than cortical) in men and women, and reduction in vertebral and nonvertebral fractures in postmenopausal women. Studies suggest that it is safe for use for up to 2 years, but further studies are needed to test longer intervals of use. Although the combination of PTH and bisphosphonates does not seem to be additive, sequential therapy of PTH followed by bisphosphonate yields maximal gains in BMD compared with combined use or monotherapy with antiresorptive agents. As our knowledge of PTH grows, this is an exciting time for researchers, clinicians, and patients who study, treat, and live with the devastating consequences of progressive osteoporosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 703-719 |
| Number of pages | 17 |
| Journal | Rheumatic Disease Clinics of North America |
| Volume | 32 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 2006 |
Fingerprint
ASJC Scopus subject areas
- Rheumatology
Cite this
Parathyroid Hormone Update. / Hamann, Kendal L.; Lane, Nancy E.
In: Rheumatic Disease Clinics of North America, Vol. 32, No. 4, 11.2006, p. 703-719.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Parathyroid Hormone Update
AU - Hamann, Kendal L.
AU - Lane, Nancy E
PY - 2006/11
Y1 - 2006/11
N2 - PTH is an exciting new treatment option for postmenopausal women and hypogonadal men who have osteoporosis. As an anabolic agent that affects bone metabolism, it represents an entirely new class of medication for osteoporosis and a novel approach to reducing fracture risk. Numerous clinical trials have demonstrated increases in trabecular and cortical BMD (trabecular more than cortical) in men and women, and reduction in vertebral and nonvertebral fractures in postmenopausal women. Studies suggest that it is safe for use for up to 2 years, but further studies are needed to test longer intervals of use. Although the combination of PTH and bisphosphonates does not seem to be additive, sequential therapy of PTH followed by bisphosphonate yields maximal gains in BMD compared with combined use or monotherapy with antiresorptive agents. As our knowledge of PTH grows, this is an exciting time for researchers, clinicians, and patients who study, treat, and live with the devastating consequences of progressive osteoporosis.
AB - PTH is an exciting new treatment option for postmenopausal women and hypogonadal men who have osteoporosis. As an anabolic agent that affects bone metabolism, it represents an entirely new class of medication for osteoporosis and a novel approach to reducing fracture risk. Numerous clinical trials have demonstrated increases in trabecular and cortical BMD (trabecular more than cortical) in men and women, and reduction in vertebral and nonvertebral fractures in postmenopausal women. Studies suggest that it is safe for use for up to 2 years, but further studies are needed to test longer intervals of use. Although the combination of PTH and bisphosphonates does not seem to be additive, sequential therapy of PTH followed by bisphosphonate yields maximal gains in BMD compared with combined use or monotherapy with antiresorptive agents. As our knowledge of PTH grows, this is an exciting time for researchers, clinicians, and patients who study, treat, and live with the devastating consequences of progressive osteoporosis.
UR - http://www.scopus.com/inward/record.url?scp=34247111392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247111392&partnerID=8YFLogxK
U2 - 10.1016/j.rdc.2006.07.005
DO - 10.1016/j.rdc.2006.07.005
M3 - Article
C2 - 17288973
AN - SCOPUS:34247111392
VL - 32
SP - 703
EP - 719
JO - Rheumatic Disease Clinics of North America
JF - Rheumatic Disease Clinics of North America
SN - 0889-857X
IS - 4
ER -